Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons

Affiliations

¹ National Plan against AIDS, Ministry of Health, Paseo del Prado 19, 28004 Madrid, Spain. jamo@mscbs.es.
² National Plan on AIDS, Ministry of Health, Madrid, Spain.
³ University Hospital Ramón y Cajal and HIV, Network of Excellence, Madrid, Spain.
⁴ National Plan on AIDS, Ministry of Health, University Hospital Ramón y Cajal, and National Center for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
⁵ HIV Network of Excellence, Madrid, and University Hospital Clinic, Barcelona, Spain.
⁶ HIV Network of Excellence and University Hospital La Paz, IdiPAZ, Madrid, Spain.
⁷ HIV Network of Excellence and National Center for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
⁸ Departments of Epidemiology and Biostatistics, Harvard School T.H. Chan of Public Health, Boston, MA; Harvard-MIT Division of Health Sciences and Technology, Boston, MA.

Comment

Julia Del Amo et al. Epidemiology. 2020 Nov.

. 2020 Nov;31(6):e49-e51.

doi: 10.1097/EDE.0000000000001235.

¹ National Plan against AIDS, Ministry of Health, Paseo del Prado 19, 28004 Madrid, Spain. jamo@mscbs.es.
² National Plan on AIDS, Ministry of Health, Madrid, Spain.
³ University Hospital Ramón y Cajal and HIV, Network of Excellence, Madrid, Spain.
⁴ National Plan on AIDS, Ministry of Health, University Hospital Ramón y Cajal, and National Center for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
⁵ HIV Network of Excellence, Madrid, and University Hospital Clinic, Barcelona, Spain.
⁶ HIV Network of Excellence and University Hospital La Paz, IdiPAZ, Madrid, Spain.
⁷ HIV Network of Excellence and National Center for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
⁸ Departments of Epidemiology and Biostatistics, Harvard School T.H. Chan of Public Health, Boston, MA; Harvard-MIT Division of Health Sciences and Technology, Boston, MA.

No abstract available

Comment on

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.
Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, Jarrín I, Hernán MA; The Spanish HIV/COVID-19 Collaboration. Del Amo J, et al. Ann Intern Med. 2020 Oct 6;173(7):536-541. doi: 10.7326/M20-3689. Epub 2020 Jun 26. Ann Intern Med. 2020. PMID: 32589451 Free PMC article.

1. The Spanish HIV/COVID-19 Collaboration. Incidence and severity of COVID-19 in HIV-positive persons on antiretroviral therapy: A cohort study. Ann Intern Med 2020. (in press). - PMC - PubMed
1. Government of Spain, Ministry of Health. Hospital survey of patients with HIV infection. Results 2019. Analysis of the evolution 2004–2019. National Center for Epidemiology–Carlos III Health Institute/National AIDS Plan–GD of Public Health, Quality and Innovation/National Center for Epidemiology; Madrid; May 2020. Accessed at 25 June 2020 https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vi...
1. Alejos B, Suárez-García I, Bisbal O, Iribarren JA, Asensi V, Górgolas M, et al. Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors. PLoS One 2019;14(8):e0221598. - PMC - PubMed
1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020. May 7;382(19):1787–1799. - PMC - PubMed
1. Stower H Lopinavir-ritonavir in severe COVID-19. Nat Med 2020; 26: 465. - PubMed